We acquired the rights to develop promising HDAC inhibitors for AI-powered cancer drug development. Read more in our press release: https://www.prnewswire.com/news-releases/kyan-therapeutics-exclusively-licenses-small-molecule-hdac-inhibitors-for-ai-powered-cancer-drug-development-301137321.html

Leave a Reply

Your email address will not be published. Required fields are marked *